Form 4: DexCom Director Mark G Foletta Receives Stock Award

Director Mark G Foletta received 2,973 shares of DexCom stock on May 22, 2024, as part of a restricted stock unit (RSU) award.

Summary

• Mark G Foletta, a director of DexCom Inc., received 2,973 shares of common stock on May 22, 2024.
• The shares were awarded as part of a restricted stock unit (RSU) grant.
• The RSU award will vest on the earlier of May 22, 2025, or the date of DexCom's 2025 Annual Meeting of Stockholders.
• Foletta also indirectly owns 62,398 shares of DexCom common stock through a trust.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The RSU award aligns the director's interests with those of the shareholders.

Future Outlook

The RSU award is designed to incentivize the director's continued service and contribution to the company's success.

Industry Context

Stock awards are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with shareholder value.

Stakeholder Impact

• The RSU award aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the award positively as a sign of the company's commitment to its leadership.

Key Dates